Hubei Kangqin Pharmaceutical Co., Ltd.

Hubei Kangqin Pharmaceutical Co., Ltd. was established in June 2013, formerly known as Hubei Kangqin Pharmaceutical Co., Ltd., and was set up through shareholding system reform in December 2015. In April 2017, it successfully listed on the "New Third Board" with stock code 871535. The company is located at No. 99 Yingchun Avenue, Jingmen High-tech Zone, Hubei Province, with a registered capital of 69.75 million yuan, 300 employees, and covers an area of 360 mu. It is a high-tech pharmaceutical enterprise integrating production, sales, and research and development.
In June 2013, the construction of the large-volume injection workshop began, covering an area of 100 mu, and in October 2014, it passed the GMP certification of the China Food and Drug Administration at one go and smoothly went into production. It is the only pharmaceutical manufacturer of large-volume injections in Jingmen City, and one of the high-tech production enterprises with the most complete varieties and specifications of large-volume injections nationwide. The company holds 21 varieties and 41 specifications of western medicine approval numbers for large-volume injections, covering most of the commonly used clinical large-volume injection varieties and specifications. Therapeutic products include Compound Glycyrrhizin Monoammonium S Sodium Chloride Injection, Alginic Acid Diester Sodium Chloride Injection, Pazufloxacin Mesylate Sodium Chloride Injection, etc.
In June 2016, the construction of a military special drug production base was initiated, covering an area of 200 mu, for the production and supply of special drugs. The production workshops, facilities, equipment, and testing instruments are newly configured and are currently the most advanced in China. Production personnel have all undergone strict training, and production conditions and management have reached the international advanced level.
To achieve long-term development, the company adheres to the integration of industry and finance and has formulated the next five-year strategic plan. The annual strategic goals are: reaching production capacity standards and reducing costs while improving efficiency (2018), expanding the market and sprinting for IPO (2019), group development with mergers and acquisitions (2020), industry-finance integration with brand strategy (2021), leading the field with a market value of 10 billion (2022).
In July 2014, the company was rated as one of the "2014 China's Top 100 Pharmaceutical Enterprises with the Most Growth Potential"; in October 2015, it passed the high-tech enterprise certification; in March 2016, it was rated as the "Jingmen Consumer Satisfaction Unit" for 2015; in May 2016, it was rated as a "Contract-Abiding and Credit-Worthy Unit" for 2014-2015; in June 2016, the China Food and Drug Administration magazine granted Hubei Kangqin Pharmaceutical Co., Ltd. the title of executive director unit of the magazine's council; in December 2016, it was awarded the honorary title of "Outstanding Contribution Unit for Military-Civilian Integration"; in 2017, the construction of the military special drug production base was listed as a provincial key construction project for 2017; in April 2017, it was rated as a national advanced collective for women's achievements; in April 2017, it was selected as the vice-chairman unit of the Eighth Executive Committee of Jingmen Federation of Industry and Commerce; in May 2017, it won the Jingmen May Day Labor Medal; in November 2017, it was awarded the title of "Advanced Growth Enterprise" by the Hubei Pharmaceutical Industry Association.